Generic Vancocin Gets Cmte. Endorsement, But So Do New Brand Products
Executive Summary
When the Pharmaceutical Science and Clinical Pharmacology Advisory Committee endorsed dissolution data for establishing bioequivalence of generic versions of Vancocin, it not only paved the way for generic applicants, but it also highlighted the need for additional, more accommodating forms of the drug
You may also be interested in...
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
FTC’s ‘Awesome’ Suit Against Shire Targets Citizen Petitions
46 filings with FDA were intended to block generic competition, FTC says in its first-ever suit over citizen petitions; role of consultants highlighted.
Vancocin Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test
FDA delivers an 87-page chef d'oeuvre that concludes the ViroPharma’s long-running battle to block ANDA approvals. In the citizen petition response, FDA rejects the firm’s scientific and legal arguments and concludes the antibiotic is not eligible for three years of Hatch-Waxman marketing exclusivity under a 2008 law. Although ViroPharma says it plans to sue FDA, the company may have bigger problems on its hands with an FTC investigation.